MX339862B - Compuestos imidazopiridinil-aminopiridina substituidos. - Google Patents

Compuestos imidazopiridinil-aminopiridina substituidos.

Info

Publication number
MX339862B
MX339862B MX2013015006A MX2013015006A MX339862B MX 339862 B MX339862 B MX 339862B MX 2013015006 A MX2013015006 A MX 2013015006A MX 2013015006 A MX2013015006 A MX 2013015006A MX 339862 B MX339862 B MX 339862B
Authority
MX
Mexico
Prior art keywords
compounds
substituted imidazopyridinyl
aminopyridine compounds
aminopyridine
methods
Prior art date
Application number
MX2013015006A
Other languages
English (en)
Other versions
MX2013015006A (es
Inventor
Kitamura Takahiro
A Ashwell Mark
Brassard Chris
Filikov Anton
Hill Jason
Koerner Steffi
Lapierre Jean-Marc
Liu Yanbin
Namdev Nivedita
Nicewonger Robert
Palma Rocio
Tandon Manish
Vensel David
Matsuda Akihisa
Iimura Shin
Yoshida Kenichi
Yamazaki Takanori
Isoyama Takeshi
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of MX2013015006A publication Critical patent/MX2013015006A/es
Publication of MX339862B publication Critical patent/MX339862B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos imidazopiridinil-aminopiridina substituidos y métodos para sintetizar estos compuestos. La presente invención también se refiere a composiciones farmacéuticas que contienen los compuestos imidazopiridinil-aminopiridina substituidos y métodos para tratar trastornos proliferativos celulares, tales como cáncer, al administrar estos compuestos y composiciones farmacéuticas a sujetos con la necesidad de los mismos.
MX2013015006A 2011-06-24 2012-06-21 Compuestos imidazopiridinil-aminopiridina substituidos. MX339862B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161500889P 2011-06-24 2011-06-24
PCT/US2012/043501 WO2012177844A2 (en) 2011-06-24 2012-06-21 Substituted imidazopyridinyl-aminopyridine compounds

Publications (2)

Publication Number Publication Date
MX2013015006A MX2013015006A (es) 2014-12-08
MX339862B true MX339862B (es) 2016-06-15

Family

ID=47362419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015006A MX339862B (es) 2011-06-24 2012-06-21 Compuestos imidazopiridinil-aminopiridina substituidos.

Country Status (16)

Country Link
US (2) US8609688B2 (es)
EP (1) EP2723741B8 (es)
JP (1) JP6046710B2 (es)
KR (2) KR101974673B1 (es)
CN (1) CN103748093B (es)
AU (2) AU2012272937B2 (es)
BR (1) BR112013033182A2 (es)
CA (1) CA2837727C (es)
DK (1) DK2723741T3 (es)
ES (1) ES2579855T3 (es)
IL (3) IL229719A0 (es)
MX (1) MX339862B (es)
PH (1) PH12013502565B1 (es)
TW (1) TWI561522B (es)
WO (1) WO2012177844A2 (es)
ZA (1) ZA201308929B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE051267T2 (hu) 2005-12-13 2021-03-01 Harvard College Sejttranszplantációs állványok
US9770535B2 (en) * 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
JP5690143B2 (ja) 2008-02-13 2015-03-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 持続的細胞プログラミング装置
WO2009146456A1 (en) * 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
CA2768552A1 (en) 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
US9073903B2 (en) * 2010-02-17 2015-07-07 Jasco Pharmaceuticals, LLC Imidazole-2,4-dione inhibitors of casein kinase 1
WO2011163669A2 (en) 2010-06-25 2011-12-29 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
US11202759B2 (en) 2010-10-06 2021-12-21 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
US10647959B2 (en) 2011-04-27 2020-05-12 President And Fellows Of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
JP6359966B2 (ja) 2011-04-28 2018-07-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 最小侵襲投与のための注射可能な予成形される肉眼的三次元スキャフォールド
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
WO2012167230A1 (en) 2011-06-03 2012-12-06 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
KR101974673B1 (ko) * 2011-06-24 2019-05-02 아르퀼 인코포레이티드 치환된 이미다조피리디닐-아미노피리딘 화합물
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
CA2938626A1 (en) 2013-07-26 2015-01-29 John Rothman Compositions to improve the therapeutic benefit of bisantrene
DK3122748T3 (en) 2014-03-24 2018-11-05 Arqule Inc METHOD OF PREPARING 3- (3- (4- (1-AMINOCYCLOBUTYL) PHENYL) -5-PHENYL-3H-IMIDAZO [4,5-B] PYRIDIN-2-YL) PYRIDIN-2-AMINE
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CA2945778A1 (en) * 2014-04-22 2015-10-29 Arqule, Inc. Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
WO2016037044A1 (en) 2014-09-05 2016-03-10 Arqule, Inc. Compositions and methods for treating proliferation disorders
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
CN105315161B (zh) * 2015-06-05 2017-08-04 厦门医学院 一类PKB/Akt抑制剂的关键中间体的制备方法
JP7138864B2 (ja) 2016-02-06 2022-09-20 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫を再構成するための造血ニッチの再現
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
JP2019522486A (ja) 2016-07-13 2019-08-15 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗原提示細胞模倣足場およびそれを作製および使用するための方法
CA3032505A1 (en) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Biomaterials for modulating immune responses
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
WO2021061837A1 (en) 2019-09-23 2021-04-01 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof
JP7808098B2 (ja) * 2020-09-30 2026-01-28 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 Ａｋｔキナーゼ阻害剤としての化合物
CN117769554A (zh) 2021-05-28 2024-03-26 大鹏药品工业株式会社 Kras突变蛋白的小分子抑制剂
WO2024039884A1 (en) * 2022-08-19 2024-02-22 Atomic Ai, Inc. Methods, systems, and media method applying machine learning to chemical mapping data for rna tertiary structure prediction
KR20250149802A (ko) * 2023-02-24 2025-10-16 테레모토 바이오사이언스, 인코포레이티드 Akt1의 공유결합 변형제 및 이의 용도
WO2025034613A1 (en) * 2023-08-04 2025-02-13 Terremoto Biosciences, Inc. 3h-imidazo[4,5-b]pyridine compounds as non-covalent modifiers of akt1 and uses thereof
TW202519211A (zh) * 2023-09-15 2025-05-16 美商亞特維斯提克生物公司 經取代之胺基吡啶化合物及用其治療疾病之方法
TW202535891A (zh) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Ｋｒａｓ蛋白之小分子抑制劑

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3722992A1 (de) 1987-07-11 1989-01-19 Thomae Gmbh Dr K Neue imidazo-pyridine und purine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2002859C (en) 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
WO1996019991A1 (en) 1994-12-28 1996-07-04 Janssen Pharmaceutica N.V. Benzimidazoles as inhibitors of calcitriol metabolism
WO1999057103A1 (en) 1998-04-30 1999-11-11 Nippon Chemiphar Co., Ltd. Condensed imidazole derivative and therapeutic agent for liver disease
JP2000344780A (ja) 1998-09-24 2000-12-12 Fuji Photo Film Co Ltd 新規ベンゾピラン化合物、発光素子材料及びそれを使用した発光素子
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0206861D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Medicaments
DK1499316T3 (da) 2002-04-18 2008-07-21 Schering Corp (1-4-piperidinyl)benzimidazolderivater anvendelige som histamin-H3-antagonister
TW200523262A (en) 2003-07-29 2005-07-16 Smithkline Beecham Corp Inhibitors of AKT activity
AU2004268950A1 (en) * 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine-derivatives as c-kit inhibitors
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
EP2298770A1 (en) 2005-11-03 2011-03-23 ChemBridge Corporation Heterocyclic compounds as TrkA modulators
JP2009521445A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション Ｈ３アンタゴニスト／逆アゴニストと食欲抑制剤との組み合わせ
RU2008141761A (ru) 2006-03-22 2010-04-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ
CN100398540C (zh) 2006-04-03 2008-07-02 大连理工大学 芳杂环基咪唑并萘酰亚胺类化合物及其应用
PL2054405T3 (pl) 2006-07-11 2014-03-31 Dae Woong Pharma Nowe pochodne biarylobenzimidazolu i zawierająca je kompozycja farmaceutyczna
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
JP2010520201A (ja) 2007-03-02 2010-06-10 シェーリング コーポレイション ベンズイミダゾール誘導体およびその使用方法
KR20100023907A (ko) 2007-06-26 2010-03-04 사노피-아벤티스 벤즈이미다졸 및 아자벤즈이미다졸의 위치선택적 구리 촉매화 합성
EP2197979B1 (en) 2007-10-17 2016-12-07 Cheil Industries Inc. Novel compound for organic photoelectric device and organic photoelectric device including the same
KR20090007347U (ko) 2008-01-16 2009-07-21 춘-치 왕 가속 페달 포지션 센서를 구비한 자동차용 연료 공급 기구
MX2012007367A (es) 2009-12-30 2013-04-03 Arqule Inc Compuestos substituidos de imidazopiridinilo-aminopiridina.
KR101974673B1 (ko) * 2011-06-24 2019-05-02 아르퀼 인코포레이티드 치환된 이미다조피리디닐-아미노피리딘 화합물
WO2012177852A1 (en) 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds

Also Published As

Publication number Publication date
EP2723741B8 (en) 2016-09-21
CA2837727C (en) 2019-12-03
CA2837727A1 (en) 2012-12-27
BR112013033182A2 (pt) 2016-09-06
TWI561522B (en) 2016-12-11
EP2723741A4 (en) 2014-12-03
WO2012177844A3 (en) 2013-04-04
JP2014517072A (ja) 2014-07-17
TW201311687A (zh) 2013-03-16
JP6046710B2 (ja) 2016-12-21
KR20140040773A (ko) 2014-04-03
KR101974673B1 (ko) 2019-05-02
WO2012177844A2 (en) 2012-12-27
EP2723741A2 (en) 2014-04-30
AU2012272937B2 (en) 2016-09-29
HK1196371A1 (zh) 2014-12-12
AU2016269408A1 (en) 2016-12-22
AU2012272937A1 (en) 2013-12-19
PH12013502565A1 (en) 2017-05-29
PH12013502565B1 (en) 2018-10-31
DK2723741T3 (en) 2016-06-06
US20140073635A1 (en) 2014-03-13
MX2013015006A (es) 2014-12-08
US8609688B2 (en) 2013-12-17
IL265897B (en) 2021-09-30
IL229719A0 (en) 2014-01-30
IL286152A (en) 2021-10-31
US8962619B2 (en) 2015-02-24
AU2016269408B2 (en) 2018-04-05
KR20190015600A (ko) 2019-02-13
ZA201308929B (en) 2016-03-30
US20120329791A1 (en) 2012-12-27
CN103748093B (zh) 2016-06-01
IL265897A (en) 2019-06-30
EP2723741B1 (en) 2016-04-27
ES2579855T3 (es) 2016-08-17
CN103748093A (zh) 2014-04-23

Similar Documents

Publication Publication Date Title
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
PH12012501337A1 (en) Substituted pyrrolo-aminopyrimidine compounds
WO2011082267A8 (en) Substituted triazolo-pyrazine compounds
WO2011082266A3 (en) Substituted heterocyclic compounds
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
MX344530B (es) Compuestos de benceno substituido.
PH12015500825A1 (en) Substituted benzene compounds
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX2015006152A (es) Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m.
PH12013500955A1 (en) Spiro-oxindole mdm2 antagonists
PH12013502118A1 (en) Aryl-or heteroaryl-substituted benzene compounds
MX394137B (es) Compuestos y composiciones novedosas para atacar las células madre del cáncer.
PH12012501556A1 (en) Substituted naphthalenyl-pyrimidine compounds
WO2012061342A3 (en) Substituted benzo-imidazo-pyrido-diazepine compounds
WO2011082271A3 (en) Substituted triazolo-pyrimidine compounds
PH12015501980A1 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
WO2012088491A3 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
WO2011082269A3 (en) Substituted benzo-pyrimido-tetrazolo-diazepine compounds
MX2012007471A (es) Compuestos substituidos de pirrolo-aminopirimidina.
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists

Legal Events

Date Code Title Description
FG Grant or registration